News

Filter

Current filters:

Vibativ

1 to 9 of 16 results

Clinigen to provide first access to anti-bacterial Vibativ in Europe

Clinigen to provide first access to anti-bacterial Vibativ in Europe

08-01-2014

UK-based Clinigen Group has announced the initiation of an early access program to provide the anti-bacterial…

Antibiotics and Infectious diseasesClinigen GroupEuropeLicensingPharmaceuticalProductionUKVibativ

Theravance reintroduces Vibativ in USA

14-08-2013

US drug developer Theravance (Nasdaq: THRX) says it has commenced shipments of Vibativ (telavancin) into…

Antibiotics and Infectious diseasesAstellas PharmaMarkets & MarketingNorth AmericaPharmaceuticalProductionTheravanceVibativ

Hikma licenses Vibativ from Theravance for MENA region

02-07-2013

Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia

03-12-2012

US drug developer Theravance (Nasdaq: THRX) saw its shares rise more than 5% $22.48 by close of trading…

Antibiotics and Infectious diseasesPharmaceuticalRegulationTheravanceVibativ

Astellas pulls out of deal with Theravance

09-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA

15-09-2011

The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

1 to 9 of 16 results

Back to top